TIM23 Complex: A Potential Drug Target and Biomarker (P24204)

Target Name: TIM23 Complex

NCBI ID: P24204

TIM23 Complex

Other Name(s): None

TIM23 Complex: A Potential Drug Target and Biomarker

TIM23 complex is a protein that is expressed in various tissues of the body, including the brain, heart, and gastrointestinal tract. It is a key regulator of the cell cycle and has been implicated in various cellular processes, including cell division, apoptosis, and tissue repair. Despite its importance, little is known about TIM23 complex and its potential as a drug target or biomarker.

The TIM23 complex is composed of two main subunits, TIM-23 and TIM-24. TIM-23 is a 21 kDa protein that contains a N-terminal transmembrane domain, a catalytic domain, and a C-terminal T-loop domain. TIM -24 is a 22 kDa protein that contains a N-terminal transmembrane domain, a catalytic domain, and a C-terminal A-loop domain.

Function

TIM23 complex plays a crucial role in regulating the cell cycle. It is involved in the transition from G1 to S phase and in the regulation of mitosis. In G1 phase, TIM23 complex is involved in the accumulation of chromosomes in the spindle, and in the metaphase, it promotes the association of sister chromatids. In S phase, TIM23 complex is involved in the disassembly of the chromatin fiber and in the recruitment of histone H3.

TIM23 complex is also involved in the regulation of apoptosis. It has been shown to play a role in the regulation of cell death in various tissues, including the brain. Studies have shown that TIM23 complex is involved in the regulation of neurodegeneration and in the development of neurotumors.

TIM23 complex is also involved in the regulation of tissue repair. It has been shown to play a role in the regulation of tissue repair following injury or disease. TIM23 complex has been shown to be involved in the recruitment of fibroblasts to the site of injury or disease. disease, and in the regulation of their proliferation.

Drug targeting

TIM23 complex is a potential drug target due to its involvement in various cellular processes. One approach to targeting TIM23 complex is to use small molecules that can modulate its activity. One such approach is the use of inhibitors of the cyclin D1-TIM23 complex, which can prevent the recruitment of TIM23 to the spindle and the association of sister chromatids.

Another approach to targeting TIM23 complex is to use antibodies that recognize and selectively target TIM23. This approach has been shown to be effective in the treatment of various diseases, including neurodegenerative diseases.

Biomarkers

TIM23 complex has also been shown to be a potential biomarker for various diseases. For example, it has been shown to be involved in the regulation of neurodegeneration, and its levels have been shown to be decreased in various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

TIM23 complex has also been shown to be involved in the regulation of cancer cell growth and has been used as a biomarker for various types of cancer, including breast cancer and lung cancer. Its levels have been shown to be increased in various types of cancer.

Conclusion

TIM23 complex is a protein that is involved in various cellular processes and has been implicated in various diseases. Despite its importance, little is known about its potential as a drug target or biomarker. The use of small molecules and antibodies to target TIM23 complex is a promising approach to the development of new treatments for various diseases. Further research is needed to fully understand the role of TIM23 complex in

Protein Name: TIM23 Complex

The "TIM23 Complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TIM23 Complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets